Relmada Therapeutics RLMD Stock
Relmada Therapeutics Price Chart
Relmada Therapeutics RLMD Financial and Trading Overview
| Relmada Therapeutics stock price | 3.25 USD |
| Previous Close | 3.6 USD |
| Open | 3.6 USD |
| Bid | 2.6 USD x 200 |
| Ask | 4.42 USD x 200 |
| Day's Range | 3.42 - 3.7 USD |
| 52 Week Range | 1.8 - 8 USD |
| Volume | 1.28M USD |
| Avg. Volume | 1.34M USD |
| Market Cap | 371.21M USD |
| Beta (5Y Monthly) | 0.513 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.75 USD |
RLMD Valuation Measures
| Enterprise Value | 153.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.487805 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.7975206 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Relmada Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.513 |
| 52-Week Change | 73.07% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 8 USD |
| 52 Week Low | 1.8 USD |
| 50-Day Moving Average | 4.53 USD |
| 200-Day Moving Average | 5.46 USD |
RLMD Share Statistics
| Avg. Volume (3 month) | 1.34M USD |
| Avg. Daily Volume (10-Days) | 1.04M USD |
| Shares Outstanding | 106.67M |
| Float | 82.64M |
| Short Ratio | 12.43 |
| % Held by Insiders | 3.23% |
| % Held by Institutions | 94.65% |
| Shares Short | 14.46M |
| Short % of Float | 14.39% |
| Short % of Shares Outstanding | 13.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.38% |
| Return on Equity (ttm) | -55.66% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -61925396 USD |
| Diluted EPS (ttm) | -0.91 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 217.73M USD |
| Total Cash Per Share (mrq) | 2.04 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 29.517 |
| Book Value Per Share (mrq) | 1.936 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -45992000 USD |
| Levered Free Cash Flow (ttm) | -23652220 USD |
Profile of Relmada Therapeutics
| Country | United States |
| State | FL |
| City | Coral Gables |
| Address | 2222 Ponce de Leon Blvd. |
| ZIP | 33134 |
| Phone | 786 629 1376 |
| Website | https://www.relmada.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Q&A For Relmada Therapeutics Stock
What is a current RLMD stock price?
Relmada Therapeutics RLMD stock price today per share is 3.25 USD.
How to purchase Relmada Therapeutics stock?
You can buy RLMD shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Relmada Therapeutics?
The stock symbol or ticker of Relmada Therapeutics is RLMD.
Which industry does the Relmada Therapeutics company belong to?
The Relmada Therapeutics industry is Biotechnology.
How many shares does Relmada Therapeutics have in circulation?
The max supply of Relmada Therapeutics shares is 106.67M.
What is Relmada Therapeutics Price to Earnings Ratio (PE Ratio)?
Relmada Therapeutics PE Ratio is now.
What was Relmada Therapeutics earnings per share over the trailing 12 months (TTM)?
Relmada Therapeutics EPS is -0.91 USD over the trailing 12 months.
Which sector does the Relmada Therapeutics company belong to?
The Relmada Therapeutics sector is Healthcare.
Relmada Therapeutics RLMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27538.69 USD — |
-0.22
|
6.46B USD — | 27341.31 USD — | 27547.2 USD — | — - | 6.46B USD — |
|
US Tech Health Care
IXHC
US
|
1295.78 USD — |
+0.26
|
— — | 1284.67 USD — | 1308.07 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
125.68 USD — |
-1.74
|
— — | 125.28 USD — | 126.01 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13561.68 USD — |
-0.2
|
— — | 13462.5 USD — | 13565.81 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6879.32 USD — |
+0.28
|
— — | 6808.22 USD — | 6956.93 USD — | — - | — — |
- {{ link.label }} {{link}}
